LGND
LGND clinical trials: LIGAND PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where LIGAND PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 41
- Trials linked
- 21
- As lead sponsor
- 20
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LGND on the catalyst calendar · LGND registry changes
- Primary completion Mar 2023Sponsor estimatePhase 2NCT04627831Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary AngiographyLigand Pharmaceuticals · Contrast-induced NephropathyWithdrawnLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2017ActualPhase 2NCT02851849A Study of LGD-6972 in Patients With Type 2 Diabetes MellitusLigand Pharmaceuticals · Type 2 Diabetes MellitusCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 1NCT02672839A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution FormulationLigand Pharmaceuticals · Type 2 Diabetes Mellitus (T2DM)CompletedLGNDLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 1NCT02250222Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes MellitusLigand Pharmaceuticals · Type 2 Diabetes MellitusCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 1NCT01919684Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2...Ligand Pharmaceuticals · Type 2 Diabetes MellitusCompletedLGNDLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00006345Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaLigand Pharmaceuticals · Drug/Agent Toxicity by Tissue/OrganCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00003752Bexarotene in Treating Patients With Metastatic Breast CancerLigand Pharmaceuticals · Breast CancerCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2008ActualPhase 2NCT00940953Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber...Ligand Pharmaceuticals · Seasonal Allergic RhinitisCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2007ActualPhase 2NCT00938613Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of ARLigand Pharmaceuticals · Seasonal Allergic RhinitisCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2008ActualPhase 2NCT00626418The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs SyndromeLigand Pharmaceuticals · Restless Legs SyndromeCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2008ActualPhase 2NCT00623324The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseLigand Pharmaceuticals · Early Stage Parkinson's DiseaseCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2008ActualPhase 2NCT00458016Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes MellitusLigand Pharmaceuticals · Type 2 Diabetes MellitusCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2008ActualPhase 2NCT00522925A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionLigand Pharmaceuticals · HypertensionCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2008ActualPhase 2NCT00635232A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With HypertensionLigand Pharmaceuticals · HypertensionCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009Sponsor estimatePhase 2NCT00879112Study of MB07811 in Subjects With HypercholesterolemiaLigand Pharmaceuticals · HypercholesterolemiaWithdrawnLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2005ActualPhase 3NCT00163137Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone LossLigand Pharmaceuticals · OsteoporosisCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2007ActualPhase 1/Phase 2NCT00073736Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular CarcinomaLigand Pharmaceuticals · Hepatocellular CarcinomaCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00674453The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine EvaluationLigand Pharmaceuticals · Bone LossCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2006ActualPhase 2NCT00143273Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose EvaluationLigand Pharmaceuticals · OsteoporosisCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2007ActualPhase 3NCT00141323Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)Ligand Pharmaceuticals · OsteoporosisCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00002212A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaLigand Pharmaceuticals · Sarcoma, KaposiCompletedLGNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2005ActualPhase 1/Phase 2NCT00238628A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerStanford University · Lung CancerCompletedLGNDCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2025ActualNo phase registeredNCT05707494Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With SepsisEfferon JSC · SepsisCompletedLGNDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2022ActualNo phase registeredNCT04827407Lipopolysaccharide Adsorption At Septic ShockEfferon JSC · Septic ShockCompletedLGNDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2023ActualPhase 1NCT05685277Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting ConditionsPharmtechnology LLC · BioequivalenceCompletedLGNDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 16 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner